This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
_256_384.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)